Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL358973 | 0.83 | ALDH1A1 (0.59) | ALDH1A1TDP1ADRA2BPTGS1CA12 | |
| SCHEMBL23487743 | 0.79 | TLR8 (0.41) | ALDH1A1HSP90AA1HSP90AB1LMNATLR8 | |
| SCHEMBL2848852 | 0.79 | GAA (0.45) | ALDH1A1TDP1ADRA2BPTGS1HSP90AA1 | |
| SCHEMBL3786877 | 0.78 | KCNH2 (0.45) | ALDH1A1TDP1ADRA2BPTGS1HSP90AA1 | |
| Nitrogen SCHEMBL27853237 | 0.78 | ALDH1A1 (0.54) | ALDH1A1TDP1ADRA2BPTGS1CA12 | |
| SCHEMBL17887314 | 0.77 | MCHR1 (0.46) | ALDH1A1CA1CA2CA7CA9 | |
| SCHEMBL3791890 | 0.77 | ALDH1A1 (0.53) | ALDH1A1GAAL3MBTL1HPGDKDM4E | |
| SCHEMBL29726496 | 0.76 | ALDH1A1 (0.65) | ALDH1A1TDP1ADRA2BPTGS1CA12 | |
| SCHEMBL78713 | 0.76 | CA12 (0.50) | ALDH1A1HSP90AA1HSP90AB1CA12CA1 | |
| SCHEMBL31607623 | 0.76 | ALDH1A1 (0.52) | ALDH1A1TDP1ADRA2BPTGS1HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118834152-A | Vilazodone derivative V02, synthesis method thereof and application thereof in preparation of antitumor drugs | 复旦大学附属肿瘤医院 | 2024-10-25 | — | — | CN | claimed |
| CN-113874372-A | Novel oxadiazole compounds for controlling or preventing phytopathogenic fungi | PI工业有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-104744311-B | Synthesis method of bifenazate | 河北美星化工有限公司 | 2017-04-26 | — | — | CN | claimed |
| EP-4642767-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | Acrivon Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2024-12-12 | — | — | US | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| CN-118852213-A | Pyrrole fused heterocyclic derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118834152-A | Vilazodone derivative V02, synthesis method thereof and application thereof in preparation of antitumor drugs | 复旦大学附属肿瘤医院 | 2024-10-25 | — | — | CN | disclosed |
| WO-2024145505-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | ACRIVON THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-4351560-A1 | ANTICANCER COMPOUNDS | The Regents of the University of California (US) | 2024-04-17 | — | — | EP | disclosed |
| US-4435336-A | FROM ARYLAMINE AND SULFONIC ACID, OR CORRESPONDING ARYLAMMONIUM HY | BAYER AKTIENGESELLSCHAFT (DE) | 1984-03-06 | — | — | US | disclosed |
| EP-0063271-A1 | Process for preparing aromatic amino-sulphonic acids | BAYER AG (DE) | 1982-10-27 | — | — | EP | disclosed |
| EP-0063269-A1 | Process for preparing amino-arylsulphonic acids | BAYER AG (DE) | 1982-10-27 | — | — | EP | disclosed |
| US-4233055-A | Quaternary ammonioalkanecarboxylic acid anilides as plant growth influencing agents | CIBA-GEIGY CORPORATION (US) | 1980-11-11 | — | — | US | disclosed |
| US-4141718-A | ANTIGROWTH AGENTS FOR PLANTS | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
| US-4112100-A | INCREASING THE ENDOGENOUS PRODUCTION OF PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4088766-A | PRODUCTION OF PROSTAGLANDINS IN MAMMALS | THE UPJOHN COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
| US-4001256-A | PROSTAGLANDIN PRODUCTION IN MAMMALS | THE UPJOHN COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
| US-3954997-A | MITICIDES, INSECTICIDES | THE UPJOHN COMPANY (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179059-A1 | ANTICANCER COMPOUNDS | BET1, BRD4, BICRA | ALDH1A1 3346/4885TDP1 2403/4885ADRA2B 3711/4885 |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | FGFR3, FGFR1, ERBB3 | ALDH1A1 4423/4885TDP1 1650/4885ADRA2B 4811/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | ALDH1A1 3346/4885TDP1 2403/4885ADRA2B 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.